Mineralys Therapeutics, Inc. (MLYS)
25.60
-0.41
(-1.58%)
USD |
NASDAQ |
Aug 28, 16:00
25.60
0.00 (0.00%)
After-Hours: 20:00
Mineralys Therapeutics Free Cash Flow : -138.80M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -138.80M |
| March 31, 2026 | -136.42M |
| December 31, 2025 | -142.43M |
| September 30, 2025 | -171.37M |
| June 30, 2025 | -192.72M |
| March 31, 2025 | -192.70M |
| December 31, 2024 | -166.41M |
| September 30, 2024 | -128.55M |
| Date | Value |
|---|---|
| June 30, 2024 | -97.36M |
| March 31, 2024 | -87.60M |
| December 31, 2023 | -81.17M |
| September 30, 2023 | -62.38M |
| June 30, 2023 | -50.34M |
| March 31, 2023 | -35.42M |
| December 31, 2022 | -29.22M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| MapLight Therapeutics, Inc. | -175.12M |
| Evommune, Inc. | -74.65M |
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -32.56M |
| Cash from Investing (Quarterly) | -185.22M |
| Cash from Financing (Quarterly) | 243.26M |
| Free Cash Flow Per Share (Quarterly) | -0.3842 |
| Free Cash Flow to Equity (Quarterly) | -130.17M |
| Free Cash Flow to Firm (Quarterly) | -32.56M |
| Free Cash Flow Yield | -6.80% |